One-year outcomes of trabeculectomy with mitomycin C in secondary glaucoma due to posner-schlossman syndrome

丝裂霉素C辅助小梁切除术治疗波斯纳-施洛斯曼综合征继发性青光眼的一年疗效

阅读:1

Abstract

To explore the effectiveness and safety of surgical treatment for patients with Posner-Schlossman syndrome (PSS) accompanied by optic nerve Changes. A retrospective analysis was conducted on 15 cases (15 eyes) of glaucoma secondary to PSS who underwent trabeculectomy from January 2018 to March 2023 at Chongqing Aier Eye Hospital. Preoperative and postoperative conditions, as well as intraocular pressure (IOP) during postoperative recurrences, were compared. 15 eyes underwent trabeculectomy, with diffuse and mildly elevated filtering blebs postoperatively, without Choroidal detachment or macular edema. The preoperative IOP was 30.91 ± 11.75 mmHg (mean ± SD), and patients used 2.60 ± 0.91 types of antiglaucoma medication. At 12 months postsurgery, the mean IOP was 12.09 ± 2.33 mmHg, and no antiglaucoma medications were used thereafter (both P < 0.05). Nine eyes experienced recurrence of PSS, with IOP during recurrences being lower than preoperative levels. Except for one eye with an IOP of 24 mmHg, the other eight eyes had IOPs not exceeding 21 mmHg. Trabeculectomy is a safe and effective treatment for patients with PSS during episodes with optic nerve damage, and it can reduce the peak IOP during recurrences, preventing further optic nerve damage from high IOP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。